Adaptive AI Transforms Cardiovascular Event Adjudication: New Algorithm Achieves Near-Human Accuracy Across Multiple Endpoints

Background: The Challenge of Cardiovascular Event Adjudication in Clinical Trials

Clinical endpoint classification (CEC) represents the gold standard for cardiovascular endpoint measurement in contemporary clinical trials. This meticulous process ensures that endpoint events are classified consistently and reproducibly, thereby minimizing bias and enhancing the validity of trial outcomes. However, the traditional CEC approach carries substantial practical burdens: it requires significant time, financial resources, and specialized expertise. As cardiovascular trials grow increasingly complex, with multiple endpoints and sophisticated composite definitions, the demand for efficient yet accurate endpoint adjudication has become more pressing than ever.

The emergence of artificial intelligence (AI) in healthcare has opened new possibilities for automating complex clinical assessments. Large language models and transformer-based architectures have demonstrated remarkable capabilities in understanding and processing medical text, raising the question of whether these technologies could be leveraged for endpoint adjudication. Yet concerns remain about the generalizability of AI systems across different trial populations, endpoint definitions, and data collection methodologies.